🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  2. ION582

    IONIS PHARMACEUTICALS INC

    Angelman syndrome

    phase 3 small molecule active

    1 trial

  3. ION582

    IONIS PHARMACEUTICALS INC

    Angelman Syndrome

    phase 3 small molecule active

    2 trials

  4. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  5. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  6. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  7. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  8. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  9. IRINOTECAN

    COLLEGIUM PHARMACEUTICAL, INC

    Gastric Carcinoma

    phase 3 small molecule active

    1 trial

  10. ISIS 3521

    IONIS PHARMACEUTICALS INC

    Lung Cancer

    phase 3 mab completed

    1 trial

  11. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    1 trial

  12. ISIS 678354, ISIS 678354, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  13. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  14. ISIS 721744, ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  15. IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  16. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  17. IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  18. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule terminated

    2 trials

  19. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  20. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  21. Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Fever

    phase 3 small molecule completed

    2 trials

  22. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Lacuna Pharma Pty Ltd

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  23. Icosapent (MND-2119)

    Mochida Pharmaceutical Company,

    Hypertriglyceridemia

    phase 3 small molecule completed

    1 trial

  24. Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources